TRIM11 promotes lymphomas by activating the β-catenin signaling and Axin1 ubiquitination degradation

Hou, Yanjin; Ding, Ming; Wang, Chen; Yang, Xiaodi; Tao, Ye; Yu, Hongmei

doi:10.1016/j.yexcr.2019.111750

Cited by 28 publications

(26 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Tripartite motif‐containing protein 11 (TRIM11) gene is located on the long arm of chromosome 1 and encodes for a protein that essentially acts as E3 ubiquitin ligase, participating in protein degradation 16 . Increased TRIM11 mRNA expression—compared to normal tissue—has been described in hepatocellular carcinoma (confirmed with TRIM11 immunohistochemical studies), 17 prostate adenocarcinoma, 18 lung non‐small cell carcinoma (NSCC), 16 colon adenocarcinoma, 19 and lymphoma 20 . In many instances, TRIM11 overexpression has been correlated with advanced stage disease 16‐18 .…”

Section: Discussionmentioning

confidence: 97%

“…Conversely, when TRIM11 was knocked down in ovarian cancer cells, in vitro upregulation of apoptotic factors and subsequent apoptosis was noted 23 . In lymphoma tissues, increased TRIM11 expression promotes proliferation possibly through activation of the b catenin/Wnt pathway 20 . In some studies, high TRIM11 expression was also recognized as an independent marker of poor prognosis in patients with lung NSCC, breast cancer, colon and prostate adenocarcinoma, glioblastoma, and HCC 16‐22 .…”

Section: Discussionmentioning

confidence: 99%

“…In lymphoma tissues, increased TRIM11 expression promotes proliferation possibly through activation of the b catenin/Wnt pathway 20 . In some studies, high TRIM11 expression was also recognized as an independent marker of poor prognosis in patients with lung NSCC, breast cancer, colon and prostate adenocarcinoma, glioblastoma, and HCC 16‐22 . Although TRIM11 expression has been examined in a variety of malignancies, data on neoplasms that lie within the differential of CRTC1‐TRIM11 melanocytic tumor are lacking.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Dermal melanocytic tumor with CRTC1‐TRIM11 fusion: Report of two additional cases with review of the literature of an emerging entity

et al. 2021

View full text Add to dashboard Cite

“Cutaneous melanocytic tumor with CRTC1‐TRIM11 fusion” (CMTCT) is a newly described, potentially novel entity that typically presents as a dermal nodule on the head and neck, extremities, and trunk of adults. Histopathologically, it is reported as a nodular or multinodular tumor composed of epithelioid and spindle cells that are variably immunoreactive for S100‐protein, SOX10, and MITF along with more specific melanocytic markers such as MelanA and HMB45. With only 11 cases reported in the English literature so far, the neoplasm appears to behave in a relatively indolent fashion. Nevertheless, in one case, local recurrence and synchronous distant metastasis were evident after 13 years. Additional cases with longer follow‐up are essential to determine the neoplasm's biologic behavior with more accuracy. Herein, two cases of CMTCT, one arising on the lower back of a 65‐year‐old female and the other on the arm of a 33‐year‐old female in addition to a comprehensive literature review are reported.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Dermal melanocytic tumor with CRTC1‐TRIM11 fusion: Report of two additional cases with review of the literature of an emerging entity

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Tripartite motif-containing protein 11 ( TRIM11 ) is a gene located on the 1q42.13 region, and encodes for a protein with E3 ubiquitin ligase activity that participates in protein degradation in various tissue types [ 15 ]. Increased TRIM11 mRNA expression-compared to normal tissue- has been described in hepatocellular carcinoma, which translated to increased protein expression by IHC [ 16 ], lung non-small cell carcinoma (NSCC) [ 15 ], prostatic, colonic, gastric adenocarcinomas [ 17 , 18 , 19 ], and lymphoma [ 20 ]. TRIM11 upregulation is also associated with increased motility, invasiveness, and cell proliferation of lung and breast cancer cells and glioblastoma cell lines [ 15 , 21 , 22 ].…”

Section: Molecular Pathogenesismentioning

confidence: 99%

“…Conversely, when TRIM11 was knocked down in ovarian cancer cells and lymphoma tissues/lymphoma cell lines in vitro, suppression of cell proliferation was observed. This was the result of either an increase in apoptotic factors or the prevention of cell cycle progression to S or G2 phase [ 20 , 23 ]. In lymphoma tissue and cell lines in particular, the knockdown of TRIM11 resulted in decreased expression of β-catenin, Cyclin D1, and c-Myc, while Axin1 was increased due to decreased ubiquitin-induced degradation.…”

Section: Molecular Pathogenesismentioning

confidence: 99%

Cutaneous Melanocytic Tumor with CRTC1::TRIM11 Fusion: Review of the Literature of a Potentially Novel Entity

Parra

Linos

2021

Biology

View full text Add to dashboard Cite

“Cutaneous melanocytic tumor with CRTC1::TRIM11 fusion” (CMTCT) is a recently described entity belonging to the family of superficial tumors displaying melanocytic differentiation. Thirteen cases have been reported so far, on the head and neck, extremities, and trunk of adults of all ages (12 cases) and one in an 11-year-old child. Histopathologically, it is a nodular or multilobulated tumor composed of spindle and epithelioid cells arranged in nests, fascicles, or bundles that are surrounded by thin collagenous septa. By immunohistochemistry, the tumor shows variable immunoreactivity for S100-protein, SOX10, and MITF, as well as specific melanocytic markers such as MelanA and HMB-45. The neoplasm’s biologic behavior remains uncertain since the reported cases are limited and the follow-up is short (median 12 months). However, local recurrence and synchronous distant metastasis after 13 years of initial resection has been described in one case. Herein, we present a comprehensive literature review of CMTCT hoping to raise awareness among the dermatopathologists of this potentially novel entity.

show abstract

Tripartite motif‐containing protein 11 promotes hepatocellular carcinogenesis through ubiquitin‐proteasome–mediated degradation of pleckstrin homology domain leucine‐rich repeats protein phosphatase 1

Yang

et al. 2022

Hepatology

View full text Add to dashboard Cite

Background and Aims: HCC is one of the main types of primary liver cancer, with high morbidity and mortality and poor treatment effect. Tripartite motif-containing protein 11 (TRIM11) has been shown to promote tumor formation in lung cancer, breast cancer, gastric cancer, and so on. However, the specific function and mechanism of TRIM11 in HCC remain open for study. Approach and Results:Through clinical analysis, we found that the expression of TRIM11 was up-regulated in HCC tissues and was associated with high tumor node metastasis (TNM) stages, advanced histological grade, and poor patient survival. Then, by gain-and loss-of-function investigations, we

show abstract

TRIM11 promotes lymphomas by activating the β-catenin signaling and Axin1 ubiquitination degradation

Cited by 28 publications

References 48 publications

Dermal melanocytic tumor with CRTC1‐TRIM11 fusion: Report of two additional cases with review of the literature of an emerging entity

Dermal melanocytic tumor with CRTC1‐TRIM11 fusion: Report of two additional cases with review of the literature of an emerging entity

Cutaneous Melanocytic Tumor with CRTC1::TRIM11 Fusion: Review of the Literature of a Potentially Novel Entity

Tripartite motif‐containing protein 11 promotes hepatocellular carcinogenesis through ubiquitin‐proteasome–mediated degradation of pleckstrin homology domain leucine‐rich repeats protein phosphatase 1

Contact Info

Product

Resources

About